NVNO enVVeno Medical Corporation logo

NVNO enVVeno Medical Corporation

Healthcare
$10.96+0.55%ClosedMarket Cap: $180,873

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

0.30

P/S

0.00

EV/EBITDA

0.09

DCF Value

$3.46

FCF Yield

-8178.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-66.4%

ROA

-72.1%

ROIC

-82.2%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-3.8M$
Q4 null$0.00$-3.7M$
FY null$0.00$-19.5M$
Q3 null$0.00$-4.5M$

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy0 Buy1 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All
Duhay Francisdirector
SellFri Mar 13
Glickman Marc H.officer: SVP & Chief Medical Officer
SellThu Dec 18
BERMAN ROBERT ANDREWdirector, officer: Chief Executive Officer
SellThu Dec 18
Alavi Hamedofficer: Chief Technology Officer
SellThu Dec 18
Shrivastava Sanjaydirector
SellMon Dec 15

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

Beta

1.08

enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

Peers